15. July 2020 | 12:23 CET
BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential
In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.
time to read: 1 minutes by Mario Hose
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Legalization in the USA is expected
Medical cannabis is already legalized in 33 states in the USA and thus about 221 million people, about 67% of the total US population, have access to the natural substance. Fifty years ago, only about 12% of US citizens were in favor of legalizing marijuana, but since then the popularity has grown to 66%.
In addition, the racism debate in the USA also plays a role in the legalization issue, because around 80% of arrests involving marijuana affect people with dark skin. For this reason, experts assume that a legalization of cannabis at the federal level will take place within the next two years - detached from the outcome of the elections in November 2020.
Recovery of the cannabis industry expected
In the tailwind of a legalization in the USA and the increasing use of cannabis in medicine, EXMceuticals and XPhyto will also grow. Both companies are active in the cannabis sector and thus part of the expanding eco-system of products, therapies and suppliers. The quality and individuality will become increasingly important.
For this reason, it can be worthwhile to focus more on smaller companies than on the big players who try to cover the whole value chain with a lot of money. Usually too much complexity leads to inefficiency. Therefore, focused niche players can have an advantage.
Vaccine can slow down Covid-19
BioNTech also focuses on individuality, as the company is working on the development of individualized options for the treatment of cancer. In addition, the biotech company is currently working with Pfizer on the development of a vaccine against Covid-19 in order to be able to limit the spread of the pandemic. In view of the fact that new hotspots of spread are constantly emerging worldwide, the global demand for a vaccine is correspondingly high.
